Who are ADL5859's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aspirin, DP, Imipenem, Cilastatin and Relebactam, Meropenem Injection, Imipenem/Cilastatin/Relebactam, Meropenem Infusion.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adl5859.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ADL5859 — Competitive Intelligence Brief

ADL5859 (ADL5859) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: carbapenem antibiotic. Area: Infectious Diseases.

phase 2 carbapenem antibiotic transpeptidase Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

ADL5859 (ADL5859) — Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). ADL5859 is a small molecule antibiotic that targets the bacterial cell wall synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ADL5859 TARGET	ADL5859	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	phase 2	carbapenem antibiotic	transpeptidase
Aspirin	acetylsalicylic acid	Bayer AG	marketed	NSAID, Antiplatelet agent	Gamma-glutamyltranspeptidase 1, Nicotinate phosphoribosyltransferase, Acid-sensing ion channel 3	1899-03-06
DP	DP	Medecins Sans Frontieres, Netherlands	marketed	Betalactam antibiotic	transpeptidase
Imipenem, Cilastatin and Relebactam	Imipenem, Cilastatin and Relebactam	Joseph L. Kuti, PharmD	marketed	Carbapenem antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); beta-lactamase inhibition
Meropenem Injection	Meropenem Injection	Institute of Liver and Biliary Sciences, India	marketed	Carbapenem antibiotic	Penicillin-binding proteins (PBPs)
Imipenem/Cilastatin/Relebactam	Imipenem/Cilastatin/Relebactam	Evopoint Biosciences Inc.	marketed	Carbapenem antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins; serine beta-lactamases
Meropenem Infusion	Meropenem Infusion	Unity Health Toronto	marketed	Carbapenem antibiotic	Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (carbapenem antibiotic class)

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
Iterum Therapeutics, International Limited · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Neutec Ar-Ge San ve Tic A.Ş · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ADL5859 — Competitive Intelligence Brief. https://druglandscape.com/ci/adl5859. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab